Legal status · United States
Is Retatrutide with cagrilintide legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. Retatrutide with cagrilintide is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 4 human studies are cited on its profile.
Retatrutide with cagrilintide in the United States at a glance
| Classification | Investigational, not approved |
|---|---|
| Note | Both components are investigational; the premixed blend is sold only by research chemical vendors and no compounding pharmacy or clinic supplies it. |
| FDA approval status | Neither component is approved anywhere in the world. Both are investigational, and no regulator has evaluated the combination. |
| Human studies cited | 4 of 4 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Retatrutide with cagrilintide profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
Retatrutide with cagrilintide is being studied in registered clinical trials but has not received FDA marketing approval in the United States.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What Retatrutide with cagrilintide is
Two unapproved investigational drugs premixed by research chemical vendors, commonly 12.5 mg retatrutide with 2.5 mg cagrilintide in one vial. Neither has finished development, no compounding pharmacy or clinic supplies the pair, and the combination has never been tested in any species. Each component separately has good phase 2 data, which is what makes this look safer than it is.
This is the most aggressive product in the metabolic section and it is worth being precise about why. Both ingredients are real investigational drugs with real trials.
Mechanism: Retatrutide agonises three receptors: GIP, GLP-1 and glucagon. The glucagon arm is what distinguishes it and is also the arm that raises energy expenditure and can affect heart rate and hepatic glucose output.
Regulatory history: Neither component is approved anywhere in the world. Both are investigational, and no regulator has evaluated the combination.
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for Retatrutide with cagrilintide at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Retatrutide with cagrilintide in other countries
United Kingdom
Not approvedInvestigational, not licensed
Is Retatrutide with cagrilintide legal in the United Kingdom?Australia
Not approvedInvestigational, not registered
Is Retatrutide with cagrilintide legal in Australia?Canada
Not approvedInvestigational, not approved
Is Retatrutide with cagrilintide legal in Canada?Frequently asked questions
Is Retatrutide with cagrilintide legal in the United States?
No. Retatrutide with cagrilintide is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 4 human studies are cited on its profile. Note: Both components are investigational; the premixed blend is sold only by research chemical vendors and no compounding pharmacy or clinic supplies it.
Can I buy Retatrutide with cagrilintide in the United States?
No approved product exists to buy. In the United States Retatrutide with cagrilintide is classified as "Investigational, not approved", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors. Note: Both components are investigational; the premixed blend is sold only by research chemical vendors and no compounding pharmacy or clinic supplies it.
Is Retatrutide with cagrilintide FDA approved?
No. FDA status: Neither component is approved anywhere in the world. Both are investigational, and no regulator has evaluated the combination.. Current US classification: "Investigational, not approved". On the evidence, 4 human studies are cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Retatrutide with cagrilintide live on its compound profile.
Retatrutide with cagrilintide profileThis page is general information about the regulatory status of Retatrutide with cagrilintide in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.